These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 17471009)

  • 21. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Lanthanum carbonate and new phosphate binders in patients with chronic kidney disease].
    Negi S; Shigematsu T
    Clin Calcium; 2010 Jul; 20(7):1096-102. PubMed ID: 20585189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hyperphosphatemia in dialysis patients: the therapeutic role of lanthanum carbonate.
    Cozzolino M; Brancaccio D
    Int J Artif Organs; 2007 Apr; 30(4):293-300. PubMed ID: 17520565
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia.
    Shigematsu T;
    Clin Nephrol; 2008 Nov; 70(5):404-10. PubMed ID: 19000540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.
    Sturtevant JM; Hawley CM; Reiger K; Johnson DW; Campbell SB; Burke JR; Bofinger A; Isbel NM
    Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of new phosphate binders for chronic renal failure.
    Loghman-Adham M
    Drug Saf; 2003; 26(15):1093-115. PubMed ID: 14640773
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure.
    Phan O; Maillard M; Malluche HH; Stehle JC; Funk F; Burnier M
    Biomed Res Int; 2015; 2015():515606. PubMed ID: 26221597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does concomitant administration of sevelamer hydrochloride and lanthanum carbonate modify the control of phosphatemia?
    Senatore M; Coppolino G; Papalia T; Greco R; Lofaro D; Bonofiglio R
    Eur Rev Med Pharmacol Sci; 2011 Nov; 15(11):1352-4. PubMed ID: 22195373
    [No Abstract]   [Full Text] [Related]  

  • 28. Three-year follow-up of lanthanum carbonate therapy in hemodialysis patients.
    Takeuchi K; Matsuda E; Sekino M; Hasegawa Y; Kamo Y; Kikuchi N; Sekino H
    Ther Apher Dial; 2013 Apr; 17 Suppl 1():15-21. PubMed ID: 23586508
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis.
    Mason MA; Shepler BM
    Pharmacotherapy; 2010 Jul; 30(7):741-8. PubMed ID: 20575637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switching from calcium carbonate to sevelamer hydrochloride has suppressive effects on the progression of aortic calcification in hemodialysis patients: assessment using plain chest X-ray films.
    Izumi M; Morita S; Nishian Y; Miyamoto T; Kasumoto H; Oue M; Hori K; Kitamura R; Yamamoto S; Nakanishi T
    Ren Fail; 2008; 30(10):952-8. PubMed ID: 19016145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy evaluation of lanthanum carbonate for hyperphosphatemia in end-stage renal disease patients.
    Shigematsu T; Ohya M; Negi S; Masumoto AR; Nakashima YM; Iwatani Y; Moribata MK; Yamanaka S; Tatsuta K; Mima T
    Contrib Nephrol; 2015; 185():42-55. PubMed ID: 26023014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral phosphate binders.
    Hutchison AJ
    Kidney Int; 2009 May; 75(9):906-14. PubMed ID: 19279554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The phosphate binder equivalent dose.
    Daugirdas JT; Finn WF; Emmett M; Chertow GM;
    Semin Dial; 2011; 24(1):41-9. PubMed ID: 21338393
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Study of prolonged administration of lanthanum carbonate in dialysis patients.
    Gotoh J; Kukita K; Tsuchihashi S; Hattori M; Iida J; Horie T; Onodera K; Furui H; Tamaki T; Meguro J; Yonekawa M; Kawamura A
    Ther Apher Dial; 2013 Apr; 17 Suppl 1():9-14. PubMed ID: 23586507
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of non-traditional phosphate binders and cinacalcet on haemodialysis patient biochemistry, pill burden and cost.
    Gray NA; Krishnasamy R; Vardesh DL; Hollett PR; Anstey CM
    Nephrology (Carlton); 2011 Nov; 16(8):688-96. PubMed ID: 21649793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Use of phosphate binder in predialysis patients].
    Taniguchi M
    Clin Calcium; 2009 Feb; 19(2):229-35. PubMed ID: 19182364
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
    Itoh K; Tanaka M; Hashiguchi J; Funakoshi S; Nakano H; Kubo H; Kono T; Uchino J; Masaki K; Date T; Shigematsu T;
    Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phosphate binders in chronic kidney disease: a systematic review of recent data.
    Floege J
    J Nephrol; 2016 Jun; 29(3):329-340. PubMed ID: 26800972
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized crossover study of the efficacy and safety of sevelamer hydrochloride and lanthanum carbonate in Japanese patients undergoing hemodialysis.
    Kasai S; Sato K; Murata Y; Kinoshita Y
    Ther Apher Dial; 2012 Aug; 16(4):341-9. PubMed ID: 22817122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic use of the phosphate binder lanthanum carbonate.
    Barton Pai A; Conner TA; McQuade CR
    Expert Opin Drug Metab Toxicol; 2009 Jan; 5(1):71-81. PubMed ID: 19236230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.